Current issues and management consensus of advanced prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference—JAPAN 2023

IF 1.8 3区医学 Q3 UROLOGY & NEPHROLOGY

International Journal of Urology Pub Date : 2024-06-01 DOI:10.1111/iju.15499

Kohei Hashimoto, Takeo Kosaka, Naoki Terada, Takahiro Kimura, Norio Nonomura, Hiroyoshi Suzuki, Hiroji Uemura

{"title":"Current issues and management consensus of advanced prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference—JAPAN 2023","authors":"Kohei Hashimoto, Takeo Kosaka, Naoki Terada, Takahiro Kimura, Norio Nonomura, Hiroyoshi Suzuki, Hiroji Uemura","doi":"10.1111/iju.15499","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>To evaluate and compare the voting results of Japanese urologists with the global panel at the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Among the 198 questions discussed at the APCCC 2022, the APCCC-JAPAN 2023 focused on 14 key questions related to the management of advanced prostate cancer with insufficient high-level evidence based on their relevance to the Japanese cohort. A panel of six prostate cancer experts addressed these 14 questions and presented the latest evidence to Japanese urologists who voted on-site using a web-based system. The results were compared with those of APCCC 2022.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>This study found significant differences in the voting results between Japanese urologists and the global panel regarding several crucial issues related to advanced prostate cancer management. These differences were those observed in treatment preferences, monitoring strategies, and treatment choices in specific clinical scenarios. These findings highlight the need for a nuanced approach tailored to the unique challenges with considerations of the Japanese healthcare environment.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>APCCC-JAPAN 2023 provides valuable insights into the current clinical issues surrounding the management of advanced prostate cancer in Japan. The partial divergence in the consensus between Japanese urologists and the global panel underscores the importance of a context-specific approach. The results of this study provide practical guidance for physicians facing complex challenges and should be used to inform decision-making in the management of advanced prostate cancer.</p>\n </section>\n </div>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Urology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/iju.15499","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

To evaluate and compare the voting results of Japanese urologists with the global panel at the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.

Methods

Among the 198 questions discussed at the APCCC 2022, the APCCC-JAPAN 2023 focused on 14 key questions related to the management of advanced prostate cancer with insufficient high-level evidence based on their relevance to the Japanese cohort. A panel of six prostate cancer experts addressed these 14 questions and presented the latest evidence to Japanese urologists who voted on-site using a web-based system. The results were compared with those of APCCC 2022.

Results

This study found significant differences in the voting results between Japanese urologists and the global panel regarding several crucial issues related to advanced prostate cancer management. These differences were those observed in treatment preferences, monitoring strategies, and treatment choices in specific clinical scenarios. These findings highlight the need for a nuanced approach tailored to the unique challenges with considerations of the Japanese healthcare environment.

Conclusions

APCCC-JAPAN 2023 provides valuable insights into the current clinical issues surrounding the management of advanced prostate cancer in Japan. The partial divergence in the consensus between Japanese urologists and the global panel underscores the importance of a context-specific approach. The results of this study provide practical guidance for physicians facing complex challenges and should be used to inform decision-making in the management of advanced prostate cancer.

查看原文本刊更多论文

晚期前列腺癌的当前问题和管理共识：日本 2023 年晚期前列腺癌共识会议报告》。

目的评估并比较日本泌尿科医生与全球专家小组在2022年晚期前列腺癌共识会议（APCCC）上的投票结果：在 APCCC 2022 讨论的 198 个问题中，APCCC-JAPAN 2023 重点讨论了与晚期前列腺癌治疗相关的 14 个关键问题，根据这些问题与日本队列的相关性，这些问题缺乏足够的高级别证据。由六位前列腺癌专家组成的小组讨论了这 14 个问题，并向日本泌尿科医生展示了最新证据，日本泌尿科医生通过网络系统进行了现场投票。投票结果与 APCCC 2022 的结果进行了比较：本研究发现，日本泌尿科医生与全球专家小组在晚期前列腺癌治疗的几个关键问题上的投票结果存在显著差异。这些差异体现在治疗偏好、监测策略和特定临床情况下的治疗选择上。这些发现突出表明，有必要针对日本医疗环境的独特挑战和考虑因素采取细致入微的方法：APCCC-JAPAN 2023 为了解当前日本晚期前列腺癌治疗的临床问题提供了有价值的见解。日本泌尿科医生与全球专家小组达成的部分共识存在分歧，这凸显了因地制宜方法的重要性。这项研究的结果为面临复杂挑战的医生提供了实用的指导，并应用于晚期前列腺癌治疗的决策参考。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Urology 医学-泌尿学与肾脏学

CiteScore

4.70

自引率

11.50%

发文量

340

审稿时长

3 months

期刊介绍： International Journal of Urology is the official English language journal of the Japanese Urological Association, publishing articles of scientific excellence in urology. Submissions of papers from all countries are considered for publication. All manuscripts are subject to peer review and are judged on the basis of their contribution of original data and ideas or interpretation.